NCT07446738 A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
| NCT ID | NCT07446738 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Chronic Rhinosinusitis With Nasal Polyps |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-03-19 |
| Primary Completion | 2027-10-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-03-19 with a primary completion date of 2027-10-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, multicenter real-world study to describe the postoperative outcomes and quality of life, disease control and characteristics of patients who underwent surgery, as well as economic burden and post-operative treatment patterns in Chinese patients with CRSwNP recurrence.
Eligibility Criteria
Inclusion Criteria: 1. Participant must be 16 years of age or older, at the time of signing the informed consent. 2. Participants with a documented diagnosis of CRSwNP. 3. Endoscopic nasal polypectomy is performed during the screening period. 4. Voluntarily participate and sign the informed consent form as described in A 3. 5. No history or current psychiatric disorders, with normal cognitive functions including understanding, expression, and orientation. Exclusion Criteria: 1. Any significant disease or disorder that the investigator believes may place the patient at risk or may affect the study results or the patient's ability to participate in the study. 2. Currently participating in an interventional study. 3. Patients who are unable to independently complete questionnaires due to language barriers or mental status.
Contact & Investigator
Weiping Wen, Professor
PRINCIPAL INVESTIGATOR
First Affiliated Hospital, Sun Yat-Sen University
Frequently Asked Questions
Who can join the NCT07446738 clinical trial?
This trial is open to participants of all sexes, studying Chronic Rhinosinusitis With Nasal Polyps. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07446738 currently recruiting?
Yes, NCT07446738 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07446738 trial being conducted?
This trial is being conducted at Changchun, China, Changsha, China, Chengdu, China, Guangzhou, China and 11 additional locations.
Who is sponsoring the NCT07446738 clinical trial?
NCT07446738 is sponsored by AstraZeneca. The principal investigator is Weiping Wen, Professor at First Affiliated Hospital, Sun Yat-Sen University. The trial plans to enroll 200 participants.